Epitomee Med(IL:EPIT)
ILAÂ 278.20+3.40 (+1.24%)
IL:EPIT
Epitomee Med financials statements
ILAÂ 278.20
At close:+3.40 (+1.24%)
Epitomee Med (EPIT) Ratios
0 Followers
Epitomee Med Ratios
IL:EPIT's free cash flow for Q2 2026 was ₪-14.78M. For the 2026 fiscal year, IL:EPIT's free cash flow was decreased by ₪-1.94M and operating cash flow was ₪-12.84M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 6.23 | 9.00 | 17.92 | 21.52 | 26.49 |
| Quick Ratio | 6.00 | 8.99 | 17.92 | 21.52 | 26.49 |
| Cash Ratio | 5.91 | 6.63 | 7.99 | 16.64 | 26.28 |
| Solvency Ratio | -1.15 | -0.17 | -0.92 | -0.95 | -0.89 |
| Operating Cash Flow Ratio | -3.28 | -3.32 | -4.05 | -4.36 | -2.35 |
| Short-Term Operating Cash Flow Coverage | -10.35 | -14.17 | -4.90 | -5.47 | -6.15 |
| Net Current Asset Value | ₪ 23.12M | ₪ 58.99M | ₪ 29.59M | ₪ 30.75M | ₪ 52.10M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.17 | 0.11 | 0.10 | 0.07 | 0.02 |
| Debt-to-Equity Ratio | 0.21 | 0.13 | 0.11 | 0.03 | 0.03 |
| Debt-to-Capital Ratio | 0.18 | 0.11 | 0.10 | 0.03 | 0.03 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.28 | 1.18 | 1.16 | 0.40 | 1.24 |
| Debt Service Coverage Ratio | -5.57 | -2.01 | -2.68 | -8.67 | -2.34 |
| Interest Coverage Ratio | -11.16 | -45.11 | -27.78 | -1006.09 | -3.24 |
| Debt to Market Cap | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 |
| Interest Debt Per Share | 0.69 | 0.56 | 0.14 | 0.14 | 0.14 |
| Net Debt to EBITDA | 0.88 | 7.74 | 2.34 | 2.12 | 7.32 |
| Profitability Margins | |||||
| Gross Profit Margin | -636.62% | 0.00% | 100.00% | 0.00% | 0.00% |
| EBIT Margin | -4475.12% | 0.00% | -56.25% | 0.00% | 0.00% |
| EBITDA Margin | -4006.32% | 0.00% | -49.86% | 0.00% | 0.00% |
| Operating Profit Margin | -4475.12% | 0.00% | -67.63% | 0.00% | 0.00% |
| Pretax Profit Margin | -4043.19% | 0.00% | -56.82% | 0.00% | 0.00% |
| Net Profit Margin | -4043.19% | 0.00% | -56.82% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | -4043.19% | 0.00% | -56.82% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 90.35% | 16.03% | 84.02% | 139.07% | 131.27% |
| Return on Assets (ROA) | -28.15% | -3.64% | -14.11% | -27.88% | -17.45% |
| Return on Equity (ROE) | -35.90% | -4.31% | -16.33% | -11.10% | -21.61% |
| Return on Capital Employed (ROCE) | -33.50% | -24.23% | -17.65% | -20.86% | -13.80% |
| Return on Invested Capital (ROIC) | -32.48% | -23.76% | -16.75% | -20.03% | -13.50% |
| Return on Tangible Assets | -28.15% | -3.64% | -14.11% | -27.88% | -17.45% |
| Earnings Yield | -16.18% | -1.92% | -5.15% | -4.62% | -1.24% |
| Efficiency Ratios | |||||
| Receivables Turnover | 1.38 | 0.00 | 16.15 | 0.00 | 0.00 |
| Payables Turnover | 5.43 | 0.42 | 4.33 | 3.90 | 0.67 |
| Inventory Turnover | 3.27 | 28.77 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.01 | 0.00 | 2.03 | 0.00 | 0.00 |
| Asset Turnover | 0.01 | 0.00 | 0.25 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.01 | 0.00 | 0.26 | 0.00 | 0.00 |
| Cash Conversion Cycle | 308.71 | -854.13 | -61.65 | -93.68 | -548.17 |
| Days of Sales Outstanding | 264.43 | 0.00 | 22.61 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 111.56 | 12.69 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 67.28 | 866.82 | 84.26 | 93.68 | 548.17 |
| Operating Cycle | 375.99 | 12.69 | 22.61 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.80 | -1.01 | -0.27 | -0.32 | -0.20 |
| Free Cash Flow Per Share | -1.01 | -1.58 | -0.41 | -0.45 | -0.21 |
| Dividend Paid and CapEx Coverage Ratio | -3.83 | -1.80 | -1.94 | -2.55 | -14.32 |
| Capital Expenditure Coverage Ratio | -3.83 | -1.80 | -1.94 | -2.55 | -14.32 |
| Operating Cash Flow Coverage Ratio | -1.36 | -1.91 | -2.00 | -2.31 | -3.80 |
| Operating Cash Flow to Sales Ratio | -32.92 | 0.00 | -0.79 | 0.00 | 0.00 |
| Free Cash Flow Yield | -16.61% | -16.94% | -10.87% | -3.93% | -0.66% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -6.17 | -51.71 | -19.42 | -21.67 | -80.82 |
| Price-to-Sales (P/S) Ratio | 249.88 | 0.00 | 11.03 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 2.22 | 2.24 | 3.17 | 2.40 | 17.46 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -6.02 | -5.90 | -9.20 | -25.42 | -151.11 |
| Price-to-Operating Cash Flow Ratio | -7.59 | -9.19 | -13.93 | -35.40 | -161.66 |
| Price-to-Earnings Growth (PEG) Ratio | -0.01 | 9.82 | 0.31 | -0.65 | -0.32 |
| Enterprise Value Multiple | -5.36 | -40.50 | -19.79 | -20.07 | -101.25 |
| Enterprise Value | 157.81M | 232.65M | 98.66M | 301.59M | 868.04M |
| EV to EBITDA | -5.36 | -40.50 | -19.79 | -20.07 | -101.25 |
| EV to Sales | 214.79 | 0.00 | 9.87 | 0.00 | 0.00 |
| EV to Free Cash Flow | -5.17 | -4.96 | -8.22 | -22.99 | -140.91 |
| EV to Operating Cash Flow | -6.52 | -7.72 | -12.45 | -32.01 | -150.75 |
| Tangible Book Value Per Share | 2.75 | 4.15 | 1.18 | 1.34 | 1.81 |
| Shareholders’ Equity Per Share | 2.75 | 4.15 | 1.18 | 4.71 | 1.81 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.02 | 0.00 | 0.34 | 0.00 | 0.00 |
| Net Income Per Share | -0.99 | -0.18 | -0.19 | -0.52 | -0.39 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 0.90 | 0.16 | 1.01 | 1.00 | 1.31 |
| Research & Development to Revenue | 22.76 | 0.00 | 0.68 | 0.00 | 0.00 |
| SG&A to Revenue | 4.86 | 0.00 | 0.07 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 2.42 | 0.00 | 0.10 | 0.00 | 0.00 |
| Income Quality | 0.81 | 5.66 | 1.39 | 0.61 | 0.50 |
Currency in ILS
